이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

CanSino Biologics 관리

관리 기준 확인 4/4

CanSino Biologics' CEO는 Xuefeng Yu, Jan2009 에 임명되었습니다 의 임기는 15.42 년입니다. 총 연간 보상은 CN¥ 3.97M, 64.1% 로 구성됩니다. 64.1% 급여 및 35.9% 보너스(회사 주식 및 옵션 포함). 는 HK$ 983.24M 가치에 해당하는 회사 주식의 11.93% 직접 소유합니다. 983.24M. 경영진과 이사회의 평균 재임 기간은 각각 6.3 년과 3.6 년입니다.

주요 정보

Xuefeng Yu

최고 경영자

CN¥4.0m

총 보상

CEO 급여 비율	64.1%
CEO 임기	15.5yrs
CEO 소유권	11.9%
경영진 평균 재임 기간	6.4yrs
이사회 평균 재임 기간	3.7yrs

최근 관리 업데이트

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

Jun 20

Recent updates

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

Jun 20

The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Apr 07

Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

Feb 06

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Oct 13

Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

Sep 07

Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts

Jul 13

Is CanSino Biologics (HKG:6185) Using Too Much Debt?

Jul 01

We Think CanSino Biologics (HKG:6185) Can Stay On Top Of Its Debt

Mar 15

CanSino Biologics Inc. (HKG:6185) Analysts Just Slashed Next Year's Revenue Estimates By 15%

Jan 11

Are Investors Undervaluing CanSino Biologics Inc. (HKG:6185) By 20%?

Dec 26

CanSino Biologics (HKG:6185) Seems To Use Debt Quite Sensibly

Oct 01

CEO 보상 분석

Xuefeng Yu 의 보수는 CanSino Biologics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-CN¥2b
Dec 31 2023	CN¥4m	CN¥3m	-CN¥1b
Sep 30 2023	n/a	n/a	-CN¥1b
Jun 30 2023	n/a	n/a	-CN¥2b
Mar 31 2023	n/a	n/a	-CN¥1b
Dec 31 2022	CN¥5m	CN¥2m	-CN¥909m

보상 대 시장: Xuefeng 의 총 보상 ($USD 546.14K )은 Hong Kong 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 450.61K ).

보상과 수익: Xuefeng 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Xuefeng Yu (59 yo)

15.5yrs

테뉴어

CN¥3,965,000

보상

Dr. Xuefeng Yu, Ph D, is Co-Founder of CanSino Biologics Inc. since 2009. Dr. Yu serves as an Executive Director at CanSino Biologics Inc. since January 13, 2009 and has served as its Chief Executive Offic...

리더십 팀

이름	위치	테뉴어	보상	소유권
Xuefeng Yu	Co-Founder	15.5yrs	CN¥3.97m	11.93% CN¥ 900.1m
Tao Zhu	Co-Founder	15.5yrs	CN¥4.42m	7.24% CN¥ 546.0m
Dongxu Qiu	Co-Founder	15.5yrs	CN¥3.74m	11.41% CN¥ 861.4m
Shou-Bai Chao	COO, Deputy GM & Executive Director	6.2yrs	CN¥3.93m	데이터 없음
Jing Wang	Chief Commercial Officer	2.8yrs	CN¥4.57m	데이터 없음
Chunlin Xin	Senior Director of New Technology Department	6.7yrs	데이터 없음	데이터 없음
Yonghui Wu	Vice President of Marketing	no data	데이터 없음	데이터 없음
Jin Cui	Board Secretary	5.3yrs	데이터 없음	데이터 없음
Ming King Chiu	Joint Company Secretary	5.3yrs	데이터 없음	데이터 없음

6.4yrs

평균 재임 기간

51yo

평균 연령

경험이 풍부한 관리: 6185 의 관리팀은 노련하고 경험 (평균 재직 기간 6.3 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Xuefeng Yu	Co-Founder	15.5yrs	CN¥3.97m	11.93% CN¥ 900.1m
Shou-Bai Chao	COO, Deputy GM & Executive Director	6.1yrs	CN¥3.93m	데이터 없음
Jing Wang	Chief Commercial Officer	2.8yrs	CN¥4.57m	데이터 없음
George R. Siber	Co-Chair of Scientific Advisory Board	1.5yrs	데이터 없음	데이터 없음
Shuifa Gui	Independent Non-Executive Director	4.7yrs	CN¥300.00k	데이터 없음
David Briles	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Luis Barreto	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Zhi Xiao	Chairman of Employee Representative Supervisor	less than a year	데이터 없음	데이터 없음
Jianzhong Liu	Independent Non-Executive Director	4.7yrs	CN¥300.00k	0.00040% CN¥ 30.2k
Liming Li	Co-Chair of Scientific Advisory Board	1.5yrs	데이터 없음	데이터 없음
Jingren Zhang	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Leung Cheung Yiu	Independent Non-Executive Director	no data	데이터 없음	데이터 없음

3.7yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 이사회: 6185 의 이사회는 경험(평균 재직 기간 3.6 년)으로 간주됩니다.

CanSino Biologics 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

CanSino Biologics Inc., Annual General Meeting, Jun 27, 2024

CanSino Biologics Inc. Announces Resignation of Nisa Bernice Wing-Yu LEUNG as Non-Executive Director and Member of the Nomination Committee

CanSino Biologics Inc. Announces Resignation of Xi LUO as Chief Financial Officer

CanSino Biologics Inc., Annual General Meeting, Jun 30, 2023

Non-Executive Director recently sold HK$3.4m worth of stock

Recent updates

CanSino Biologics Inc. to Report First Half, 2024 Results on Aug 30, 2024

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

CanSino Biologics Inc., Annual General Meeting, Jun 27, 2024

CanSino Biologics Inc. Announces Resignation of Nisa Bernice Wing-Yu LEUNG as Non-Executive Director and Member of the Nomination Committee

Consensus EPS estimates upgraded to CN¥1.19 loss

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Cansino Biologics Inc. Announces Positive Preliminary Results from Phase I Clinical Trials of the Protein-Based Pneumococcal Vaccine

The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Full year 2023 earnings: EPS and revenues miss analyst expectations

CanSino Biologics Inc. to Report Q1, 2024 Results on Apr 30, 2024

Consensus EPS estimates upgraded to CN¥1.04 loss, revenue downgraded

Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Acceptance of Drug Registration Application for 13-Valent Pneumococcal Conjugate Vaccine

Full year 2023 earnings: EPS and revenues miss analyst expectations

Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023

CanSino Biologics Inc. Obtains the Final Report of Phase III Clinical Trial Of 13-Valent Pneumococcal Conjugate Vaccine

Cansino Biologics Inc. Announces Phase I Clinical Trial and Completion of First Patient Case for Recombinant Poliomyelitis Vaccine

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Patient Enrollment for TDCP Adolescent and Adult

CanSino Biologics Inc. Announces Resignation of Xi LUO as Chief Financial Officer

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case

Third quarter 2023 earnings released

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

Second quarter 2023 earnings released: CN¥2.82 loss per share (vs CN¥0.44 loss in 2Q 2022)

New minor risk - Share price stability

CanSino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc. Announces CS-2032 Zoster Vaccine Obtains Clinical Trial Approval from Canada

CanSino Biologics Inc. to Report First Half, 2023 Results on Aug 22, 2023

Cansino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc., Annual General Meeting, Jun 30, 2023

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Full year 2022 earnings released: CN¥3.65 loss per share (vs CN¥7.74 profit in FY 2021)

Consensus EPS estimates fall by 49%

CanSino Biologics Inc. Provides Earnings Guidance for the Period from January 1, 2022 to December 31, 2022

Non-Executive Director recently sold HK$3.4m worth of stock

Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet?

Cansino Biologics Inc. Announces Covid-19 Mrna Vaccine Cs-2034 Achieved Positive Interim Data in A Clinical Trial Evaluating the Safety and Immunogenicity of the Heterologous Cs-2034 Booster

CanSino Biologics Inc. Announces Clinical Research Results of A Clinical Trial of Bivalent Recombinant Covid-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation in Adults Aged 18 Years and Above

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

Less than half of directors are independent

CanSino Biologics Inc.'s Recombinant Covid-19 Vaccine (Adenovirus Type 5Vector) for Inhalation Approved for Emergency Use in Morocco

Consensus EPS estimates fall by 73%

Consensus revenue estimates fall by 12%

Now 38% undervalued

Third quarter 2022 earnings released

Investor sentiment improved over the past week

CanSino Biologics Inc. to Report Q3, 2022 Results on Oct 28, 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

CanSino Biologics Inc.'s (HKG:6185) Share Price Not Quite Adding Up

CanSino Biologics Inc. Recombinant Covid-19 Vaccine for Inhalation Included for Emergency Use as A Booster Vaccine in PRC

Consensus revenue estimates fall by 41%

Investor sentiment deteriorated over the past week

Things Look Grim For CanSino Biologics Inc. (HKG:6185) After Today's Downgrade

Should You Be Adding CanSino Biologics (HKG:6185) To Your Watchlist Today?

Second quarter 2022 earnings released: CN¥0.44 loss per share (vs CN¥3.67 profit in 2Q 2021)

CanSino Biologics Inc. to Report Q2, 2022 Results on Aug 26, 2022

Investor sentiment deteriorated over the past week

Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts

Consensus revenue estimates fall by 12%

Is CanSino Biologics (HKG:6185) Using Too Much Debt?

Cansino Biologics Inc. Announces Dividend for the Financial Year Ended December 31, 2021 Payable on 19 August 2022

Investor sentiment improved over the past week

CanSino Biologics Inc., Annual General Meeting, Jun 29, 2022

CanSino Biologics Inc., Annual General Meeting, Jun 29, 2022

CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing